 Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.840.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in UAMS Profiles by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 0 | 1 | 1 | | 2017 | 1 | 2 | 3 | | 2016 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 3 | 4 | | 2013 | 2 | 2 | 4 | | 2011 | 1 | 2 | 3 | | 2010 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2006 | 2 | 3 | 5 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles over the past ten years.
-
Harmatz IM, Alkhatib KY, Leff M, Nolazco JI, Michel KF, Slinger M, McLauchlan N, Cortese BD, Roberson DS, Schurhamer B, Lee DJ, Malkowicz SB, Trinh QD, Bivalacqua TJ, Guzzo TJ, Pierorazio PM. Prostate-Specific Antigen Screening in Smokers: A Comprehensive Analysis Using a National Behavioral Survey. Urol Pract. 2024 May; 11(3):547-556.
-
Eichhorn J, Nelson N, Raichandani S, Sesler A, Palot Manzil FF. Prostate-Specific Membrane Antigen PET/CT Detection of Prostate Cancer Metastasis to Thyroid and Cricoid Cartilages. Clin Nucl Med. 2024 May 01; 49(5):481-483.
-
Nakamura N, Rogers P, Eggerson R, Post SR, Davis R. Translational Research for Identifying Potential Early-stage Prostate Cancer Biomarkers. Cancer Genomics Proteomics. 2023 Jan-Feb; 20(1):1-8.
-
Tosoian JJ, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder CY, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology. 2022 06; 164:184-190.
-
Nandakumar V, Bornhorst JA, Algeciras-Schimnich A. Evaluation of Phi Clinical Performance for the Detection of Prostate Cancer in Routine Clinical Practice. Ann Clin Lab Sci. 2021 Jan; 51(1):3-11.
-
Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
-
Kunthur A. A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. J Oncol Pharm Pract. 2020 Jul; 26(5):1254-1258.
-
Osmany S, Zaheer S, Bartel TB, Johnston M, Peh WM, Barmaky S, Jadvar H. Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers. AJR Am J Roentgenol. 2019 08; 213(2):286-299.
-
Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Ann Nucl Med. 2019 May; 33(5):326-332.
-
Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 07; 122(1):50-58.
-
Gilbert SM, Dunn RL, Miller DC, Montgomery JS, Skolarus TA, Weizer AZ, Wood DP, Hollenbeck BK. Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 09; 198(3):600-607.
-
McClinton C, Niroumand M, Sood S, Shah V, Hill J, Dusing RW, Shen X. Patterns of lymph node positivity on 11C-acetate PET imaging in correlation to the RTOG pelvic radiation field for prostate cancer. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):325-331.
-
Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357.
-
Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, Choi YD, Rha KH. Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to =8 among patients with biopsy Gleason score 6. Investig Clin Urol. 2017 03; 58(2):90-97.
-
Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L. Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate. 2016 09; 76(12):1053-66.
-
Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
-
de la Rosette J, Elhilali M, Naito S, Unal D, Razvi H, Liatsikos E, Bachmann A, Tubaro A, Alivizatos G, Mak SK, Badlani G, Eltahawy E, Wong C, Telich Vidal M, Te A, d'Ancona F, Arum CJ, Gutierrez J. Clinical Research Office of the Endourological Society Global GreenLight Laser Study: Outcomes from a contemporary series of 713 patients. Int J Urol. 2015 Dec; 22(12):1124-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|